Goldman on Vertex: We Await Orkambi Pricing Details, Expect To Be On Par WIth Kalydeco ($312K/Yr) Given Strong Secondary Endpoint And Historical Analysis Of Orphan Drug Pricing

By: via Benzinga
Goldman expects investor focus to shift over to the drug's trajectory and company's earnings power.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.